Sodium zirconium cyclosilicate is a potassium binder used to treat hyperkalemia. It is administered orally and is odorless, tasteless, and stable at room temperature.
- Mechanism
- Curator reviewed · 8 references
Hyperkalemia is a condition defined by elevated potassium levels in the blood, often caused by cardiovascular, renal, and metabolic diseases. Hyperkalemia occurs in 23 to 47% of patients with chronic kidney disease and/or chronic heart failure, and may lead to cardiac arrest and death.
Sodium zirconium cyclosilicate is subsequently a non-absorbed, non-polymer inorganic powder with a uniform micropore structure that preferentially captures potassium in exchange for hydrogen and sodium cations. Sodium zirconium cyclosilicate is highly selective for potassium ions, even in the presence of other cations such as calcium and magnesium, in vitro. Sodium zirconium cyclosilicate captures potassium throughout the entire gastrointestinal (GI) tract and reduces the concentration of free potassium in the GI lumen, thereby lowering serum potassium levels and increasing fecal potassium excretion to resolve hyperkalemia.
- Primary indication
- Sodium zirconium cyclosilicate is a potassium binder indicated for the treatment of hyperkalemia in adult patients.Curator reviewed · 1 structured indication
- Formula / weight
- Na2O9Si3Zr · 365.452 g/mol (avg)
- First approval
- Canada, 2019 · United States, 2018 · European Union, 2020
- Also known as
- Sodium zirconium silicate
- Code names
- UXSI-9 · ZS · ZS-9
- Brand names
Resolves to
ARVUQMBOTBOHPL-UHFFFAOYSA-NSMILES[Na+].[Na+].[Zr].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1What you can answer from here — as of December 05, 2023
Which other approved drugs treat the same conditions as Sodium zirconium cyclosilicate, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account